Atlas Venture Closes Fund XII at $400 Million, Promotes Gladstone to Partner

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.


You may also like

SpringWorks Faces Readout for Gamma Secretase Inhibitor; Eyes BCMA Combo for Cancer
Versant Ventures Wagers $35M on Cytokine Engineering with Bright Peak
Seer Raises $55 Million; Describes Novel Proteomic Technology
The Vintage of 2020: How COVID-19 is Molding Biotech Startups